MR mismatch is useful for patient selection for thrombolysis: Yes

Stroke

Volumn 40, Issue 8, 2009, Pages 2906-2907

  Fiebach, Jochen B ^a   Schellinger, Peter D ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Controversies; Diffusion weighted imaging; MR mismatch; Thrombolysis

Indexed keywords

ALTEPLASE;

BLOOD CLOT LYSIS; CLINICAL TRIAL; COMPUTER PROGRAM; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; OUTCOMES RESEARCH; PATIENT SELECTION; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; SHORT SURVEY; STROKE;

DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOLYTIC THERAPY;

EID: 68749092874     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.552877     Document Type: Short Survey

References (10)

1. Schellinger PD, Jansen O, Fiebach JB, Heiland S, Steiner T, Schwab S, Pohlers O, Ryssel H, Sartor K, Hacke W. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke. 2000;31:1318-1328.
2. Schlaug G, Benfield A, Baird AE, Siewert B, Lovblad KO, Parker RA, Edelman RR, Warach S. The ischemic penumbra: Operationally defined by diffusion and perfusion MRI. Neurology. 1999;53:1528-1537.
3. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.
4. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
5. Kohrmann M, Juttler E, Fiebach JB, Huttner HB, Siebert S, Schwark C, Ringleb PA, Schellinger PD, Hacke W. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: A cohort study. Lancet Neurol. 2006;5:661-667.
6. Schellinger PD, Thomalla G, Fiehler J, Kohrmann M, Molina CA, Neumann-Haefelin T, Ribo M, Singer OC, Zaro-Weber O, Sobesky J. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: An analysis of 1210 patients. Stroke. 2007;38:2640-2645.
7. Thomalla G, Schwark C, Sobesky J, Bluhmki E, Fiebach JB, Fiehler J, Zaro Weber O, Kucinski T, Juettler E, Ringleb PA, Zeumer H, Weiller C, Hacke W, Schellinger PD, Rother J. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: Comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke. 2006;37:852-858.
8. Albers GW, Thijs V, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Marks MP, Kakuda W, Lansberg M, Shuaib A, Coplin W, Moseley M. Results of the Diffusion-Weighted Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Stroke. 2006;37: 635-636.
9. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309.
10. Wintermark M, Albers GW, Alexandrov AV, Alger JR, Bammer R, Baron JC, Davis S, Demaerschalk BM, Derdeyn CP, Donnan GA, Eastwood JD, Fiebach JB, Fisher M, Furie KL, Goldmakher GV, Hacke W, Kidwell CS, Kloska SP, Kohrmann M, Koroshetz W, Lee TY, Lees KR, Lev MH, Liebeskind DS, Ostergaard L, Powers WJ, Provenzale J, Schellinger P, Silbergleit R, Sorensen AG, Wardlaw J, Wu O, Warach S. Acute stroke imaging research roadmap. Stroke. 2008;39:1621-1628.